CHARMD
Comprehensive Herpesviruses Antiviral drug Resistance Mutation Database
English (en)
Français (fr)
Español (es)
CNR Website
Home
Login
Data
All data
Antivirals
Bibliography
Therapeutic targets
Tools
Search
Submit mutations
Request expertise
Genotyping tool
Gene maps
Contact
Notice
How to cite
Last update : Mon 20 Apr 2026
TOP
Marfori JE
References:
Rank: 1 -
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients.(Feb 2007)
Filter:
Mutant
Gene
Virus
Reference
Mutations:
D413A
UL54
Human betaherpesvirus 5
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
D413A
UL54
Human betaherpesvirus 5
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
D413A
UL54
Human betaherpesvirus 5
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
601-602del
UL97
Human betaherpesvirus 5
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
601-603del
UL97
Human betaherpesvirus 5
Development of new cytomegalovirus UL97 and DNA polymerase mutations conferring drug resistance after valganciclovir therapy in allogeneic stem cell recipients. (Feb 2007)
Tilloy
et al.
, 2024
Interdeposit Digital Number: IDDN.FR.001.420004.000.S.X.2024.000.31230
